皮下与舌下免疫治疗成人过敏性鼻炎的荟萃分析
该系统综述与荟萃分析基于Cochrane手册和PRISMA,检索四个数据库至2020年7月30日,纳入7项SCIT与SLIT直接比较的RCT及46项间接比较RCT。调整间接比较显示SCIT和SLIT对症状评分、药物评分、联合评分和生活质量均显著优于安慰剂,但两者之间无显著差异,结论为SCIT与SLIT疗效相当。
要点
- SCIT与SLIT在改善症状评分、药物评分、联合评分和生活质量上均显著优于安慰剂。
- 调整间接比较显示SCIT与SLIT之间在上述所有结局上均无显著差异。
- 直接比较SCIT与SLIT的RCT仅7项且数据不足,无法进行直接荟萃分析。
核心结论
- SCIT和SLIT是成人过敏性鼻炎/结膜炎疗效相当的治疗选择。
- 需要更多直接比较SCIT与SLIT的RCT来验证两者差异。
研究设计与样本
- 系统综述与荟萃分析,方法基于Cochrane手册和PRISMA。
- 检索PubMed、Cochrane Library、EMBASE和Web of Science从建库至2020年7月30日。
- 纳入7项SCIT与SLIT直接比较的RCT;调整间接比较纳入46项RCT(39项研究),其中SCIT vs 安慰剂13项,SLIT vs 安慰剂33项。
- 两位独立评审员筛选文献并评估偏倚风险,使用RevMan 5.4.1进行荟萃分析和调整间接比较。
主要发现
- SCIT vs 安慰剂:症状评分SMD=0.40(95%CI 0.31-0.49),药物评分SMD=0.26(95%CI 0.14-0.39),联合评分SMD=0.42(95%CI 0.17-0.67),RQLQ MD=0.24(95%CI 0.04-0.44)。
- SLIT vs 安慰剂:症状评分SMD=0.42(95%CI 0.32-0.53),药物评分SMD=0.40(95%CI 0.28-0.53),联合评分SMD=0.37(95%CI 0.29-0.45),RQLQ MD=0.32(95%CI 0.20-0.43)。
- SCIT vs SLIT(调整间接比较):症状评分SMD=-0.02(95%CI -0.15至0.11),药物评分SMD=-0.14(95%CI -0.31至0.03),联合评分SMD=0.05(95%CI -0.21至0.31),RQLQ MD=-0.08(95%CI -0.31至0.15),均无显著差异。
- 7项直接比较SCIT与SLIT的RCT显示所有结局均无显著差异,但数据不足无法进行直接荟萃分析。
临床怎么用
- 对于成人过敏性鼻炎/结膜炎患者,SCIT和SLIT均可作为有效的免疫治疗选择,疗效相当。
- 临床选择SCIT或SLIT时可综合考虑患者偏好、依从性、安全性和可及性,而非仅基于疗效差异。
局限性
- 直接比较SCIT与SLIT的RCT仅7项且数据不足,无法进行直接荟萃分析。
- SCIT与SLIT的疗效比较主要基于调整间接比较,而非头对头直接比较。
- 需要更多直接比较SCIT与SLIT的RCT来验证两者差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) better improves patient outcomes and quality of life for adults with allergic rhinitis or rhinoconjunctivitis (AR/C) with or without mild to moderate asthma. METHODS: Systematic review methodology was based on the Cochrane Collaboration handbook and Preferred Reporting Items for Systematic Reviews and Meta-analyses. Four databases (PubMed, Cochrane Library, EMBASE, and Web of Science) were queried from inception to July 30, 2020. Two independent reviewers screened potentially relevant studies and assessed risk of bias. Outcomes of interest were symptom score (SS), medication score (MS), combined symptom medication score (CSMS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Meta-analyses with an adjusted indirect comparison were conducted in RevMan 5.4.1. RESULTS: Seven SCIT versus SLIT randomized controlled trials (RCTs) demonstrated no significant differences for any outcomes, but insufficient data precluded direct meta-analysis. For the adjusted indirect comparison, 46 RCTs over 39 studies were included for SCIT versus placebo (n = 13) and SLIT versus placebo (n = 33). Statistically significant results favoring SCIT were found for SS (standardized mean difference [SMD] = 0.40; 95% confidence interval [CI] = 0.31-0.49), MS (SMD = 0.26; 95% CI = 0.14-0.39), CSMS (SMD = 0.42; 95% CI = 0.17-0.67), and RQLQ (MD = 0.24; 95% CI = 0.04-0.44). Statistically significant results favoring SLIT were found for SS (SMD = 0.42; 95% CI = 0.32-0.53), MS (SMD = 0.40; 95% CI = 0.28-0.53), CSMS (SMD = 0.37; 95% CI = 0.29-0.45), and RQLQ (MD = 0.32; 95% CI = 0.20-0.43). No significant differences were found between SCIT and SLIT for SS (SMD = -0.02; 95% CI = -0.15 to 0.11), MS (SMD = -0.14; 95% CI = -0.31 to 0.03), CSMS (SMD = 0.05; 95% CI = -0.21 to 0.31), or RQLQ (MD = -0.08; 95% CI = -0.31 to 0.15). CONCLUSION: SCIT and SLIT are comparably effective treatments for adults with AR/C. More RCTs analyzing SCIT versus SLIT are needed to directly compare the two. Laryngoscope, 132:499-508, 2022.
引用
- Tie K, Miller C, Zanation AM, et al. Subcutaneous Versus Sublingual Immunotherapy for Adults with Allergic Rhinitis: A Systematic Review with Meta-Analyses. Laryngoscope. 2021. PMID: 33929726. doi:10.1002/lary.29586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。